AC
CRBP icon

Armistice Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Armistice Capital’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.42M Sell
364,000
-172,000
-32% -$1.45M 0.06% 138
2025
Q4 		$4.36M Buy
536,000
+344,000
+179% +$4.25M 0.05% 131
2025
Q3 		$2.43M Hold
192,000
– – 0.04% 143
2025
Q2 		$1.32M Sell
192,000
-58,000
-23% -$421K 0.02% 143
2025
Q1 		$1.33M Buy
250,000
+14,000
+6% +$124K 0.02% 156
2024
Q4 		$2.78M Buy
+236,000
New +$3.96M 0.04% 137

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Armistice Capital's CRBP Position: Q1 2026 in Review

Armistice Capital reduced its Corbus Pharmaceuticals (CRBP) stake by 32% in Q1 2026, selling an estimated $1.45M and leaving 364,000 shares worth $3.42M. The position accounts for 0.06% of the portfolio, ranked #138.

Armistice Capital first reported a position in CRBP in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.36M in Q4 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Armistice Capital held 364,000 shares of Corbus Pharmaceuticals worth $3.42M as of Q1 2026.
  • Armistice Capital sold 172,000 Corbus Pharmaceuticals shares in Q1 2026, an estimated $1.45M.
  • Corbus Pharmaceuticals made up 0.06% of Armistice Capital's portfolio in Q1 2026, its #138 holding.
  • Armistice Capital first reported a position in Corbus Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Armistice Capital's Corbus Pharmaceuticals position peaked at $4.36M in Q4 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.